Vevoctadekin
PreclinicalBiologic
Vevoctadekin is one of 19 biologic programs targeting Recurrent Diffuse Large B-Cell Lymphoma. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Recurrent Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 2
Epkinly
GenmabPhase 2
Gemzar
Johnson & JohnsonPhase 2
Cytosar
TevaPhase 2
Eloxatin
TevaPhase 2
LUNSUMIO
RochePhase 2
Paraplatin
AAvyxa
Phase 2
Etopophos
GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 2
Ifex
BBaxter Healthcare Corporation
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vevoctadekin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Washington